Navigation Links
Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
Date:2/25/2009

p>Pain represents a large and dynamic market in the United States. Oral formulations of NSAIDs currently are marketed worldwide for the treatment of inflammation and pain, including pain due to musculoskeletal injuries, signs and symptoms of osteoarthritis and rheumatoid arthritis, menstrual cramps, headache and other minor aches and pains. While traditional oral NSAIDs are effective, they can cause serious gastrointestinal and other adverse events. Further, the withdrawal of some COX-2 inhibitors has removed a major therapeutic option for patients with multiple moderate and severe forms of pain, resulting in a significant market opportunity. These developments have created a significant need for a localized pain product with a strong safety profile.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for pain and inflammation. Cerimon's lead product, its topical diclofenac patch, has begun its Phase III program, which includes three studies for the treatment of mild-to-moderate pain due to acute ankle sprain, wrist injury or soft tissue injury. The Company initiated its pivotal program based on positive results from Cerimon's Phase II SUPPORT (Stop Underlying Pain with a diclofenac Patch and Obtain Relief Topically) ankle sprain study. A topical diclofenac lotion is also in development.

Cerimon is financed by the premier investors MPM, Normura Phase4 and OrbiMed Advisors. For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The National Model Aviation Museum, located at ... to announce that it has been granted full civilian ... States Air Force. , The certification is the culmination ... spring with an on-site inspection by Sarah Sessions, Museum ... National Museum of the United States Air Force ...
(Date:7/25/2014)... study by researchers from the University of Leicester ... function, unlocking the potential to create new materials ... has been published in the prestigious academic journal ... laser technique to examine in rich detail the ... cluster containing an acetylene molecule and a single ...
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology Technology:AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Ariz., May 31, 2011 Regal One Corporation (OTCBB:RONE), ... on incubating and bringing public high quality companies, today ... shares of Rampart Detection Systems Ltd Common stock. Regal ... registration statement with the United States Securities and Exchange ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at ... 7, 2011, at 12:20 p.m. ET / 9:20 a.m. ... Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 ... New York.  Daniel M. Bradbury, president and chief executive ...
... RALEIGH, N.C., May 31, 2011 Today, Campbell Alliance released ... latest in its Landmark Study series.  A summary report of ... the firm is sharing a more in-depth presentation of the ... Study explores the factors that have caused major changes in ...
Cached Biology Technology:Regal One Announces Dividend of Rampart Detection Systems Common Stock 2Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products 2
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/27/2014)... single computer cannot always find the solution a user ... cluster of computers that analyze a massive data set ... history to present you with targeted ads, and how ... movie. But big data is about more than just ... are generating unprecedented quantities of information. That data may ...
(Date:7/25/2014)... first broad-scale estimate of air pollution removal by trees ... trees are saving more than 850 human lives a ... , While trees, pollution removal equated to an average ... impacts of that improvement are substantial. Researchers valued the ... nearly $7 billion every year in a study published ...
Breaking Biology News(10 mins):Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5First national study finds trees saving lives, reducing respiratory problems 2
... Bad drivers may in part have their genes to blame, ... a particular gene variant performed more than 20 percent worse on ... test a few days later yielded similar results. About 30 percent ... from the get-go, and they forget more of what they learned ...
... OCTOBER 27, 2009 -- The 2009 Annual Meetings of ... of America (CSSA), and Soil Science Society of America ... Pittsburgh, PA. The meeting,s theme, "Footprints in the Landscape: ... location in the LEED-certified David L. Lawrence Convention Center ...
... WHAT: DigitalPersona Vice President of Marketing, Jim ... the Industry Expert Panel on Endpoint Security. Discussing the ... Fulton will describe how enterprises can address security vulnerabilities ... examine how the implementation of identity-aware security offerings shifts ...
Cached Biology News:Bad driving may have genetic basis, UCI study finds 22009 Annual Meetings emphasize sustainability 2DigitalPersona to Speak at Dallas SecureWorld Expo 2
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Siglec-9 Biotinylated Affinity Purified Pab...
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
Human RELT/TNFRSF19L MAb (Clone 238104)...
Biology Products: